查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954217

产前和新生儿基因检测市场分析及预测（至2035年）：类型、产品类型、服务、技术、应用、最终用户、流程、模式和阶段

Prenatal and Newborn Genetic Testing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 385 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，产前和新生儿基因检测市场规模将从2024年的81亿美元成长至165亿美元，年复合成长率约为7.5%。该市场涵盖孕期和出生后进行的诊断和筛检测试，旨在识别遗传疾病和染色体异常。基因组技术的进步、父母意识的提高以及对早期诊断需求的成长是推动市场成长的主要因素。主要细分市场包括非侵入性产前检测（NIPT）、带因者筛检和新生儿筛检。随着精准医疗的发展，该市场有望实现成长。精准医疗的特点是注重个人化医疗解决方案和提高遗传咨询服务的可近性。

受基因组技术进步和意识提升的推动，产前和新生儿基因检测市场持续强劲成长。按细分市场划分，产前筛检检测的成长速度最快，这主要得益于非侵入性产前检测 (NIPT) 的技术创新以及对早期发现遗传疾病日益增长的需求。 NIPT 凭藉其高准确性和安全性，仍然是一个重要的细分市场，吸引着医疗保健提供者和准妈妈们的注意。紧随其后的是新生儿基因检测领域，尤其是在代谢紊乱筛检和全基因测序，也呈现出良好的成长动能。这些细分市场之所以发展迅速，是因为它们具有早期识别罕见遗传疾病并实现及时介入的潜力。人工智慧和机器学习在基因数据分析中的应用提高了检测的准确性和效率，进一步推动了市场成长。随着个人化医疗的不断发展，对综合基因检测解决方案的需求预计将会增加，从而为相关人员创造盈利的机会。

市场区隔
类型 产前筛检、新生儿筛检、基因带原检测、诊断性检测
产品 设备、试剂盒及试剂、软体、耗材
服务 遗传咨询、检测服务和数据分析
科技 次世代定序、聚合酵素链锁反应、微阵列、萤光原位杂合反应
应用领域 染色体异常、遗传性疾病、代谢性疾病
最终用户 医院、诊断检查室、研究中心和专科诊所
过程 检体采集、DNA提取、定序和数据分析
实作方法 侵入性、非侵入性
步 怀孕前、生产前、分娩后

受多种新产品的推出推动，产前和新生儿基因检测市场正经历动态的竞争格局。提供利用先进技术的综合检测解决方案的公司占据了相当大的市场份额。由于企业需要在价格亲民和高成本之间取得平衡，定价策略的竞争日益激烈。新调查方法的引入正在重塑消费者的预期，并推动市场在各个地区的扩张。竞争基准研究揭示了市场集中度较高的格局，主要企业都在加大研发投入以维持其竞争优势。监管的影响显着，严格的指导方针影响产品开发和打入市场策略。法规环境的区域差异进一步加剧了市场的复杂性，因此需要灵活的合规策略。技术进步和人们对基因检测益处的日益了解正在推动市场成长。这项全面的分析支持了市场的潜力，并突显了策略投资和合作的机会。

主要趋势和驱动因素：

受技术进步和人们对遗传疾病认识不断提高的推动，产前和新生儿基因检测市场正处于成长轨道上。一个关键趋势是，由于其准确性和安全性，非侵入性产前检测 (NIPT) 的普及率不断提高。这一趋势，加上人工智慧和巨量资料分析的整合，正在推动诊断准确性的提高和个人化医疗方案的实施。此外，政府主导和父母意识提升的增强也推动了对全面新生儿筛检计画的需求激增。遗传疾病和先天性异常的盛行率不断上升，需要早期发现和干预，这进一步推动了市场成长。新兴国家对预防性医疗保健的日益重视和医疗基础设施的不断改善也是市场成长的驱动因素。此外，医疗服务提供者和基因检测公司之间的合作正在推动创新并提高服务的可及性。个人化检测套组的开发和远距远端医疗服务的扩展，为偏远和医疗资源匮乏地区提供了发展机会。在不断变化的伦理考量和法规结构下，预计该市场将继续与全球医疗保健优先事项保持一致，并持续扩张。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 产前筛检
    • 新生儿筛检
    • 基因带原检测
    • 诊断测试
  • 市场规模及预测：依产品划分
    • 装置
    • 试剂盒和试剂
    • 软体
    • 消耗品
  • 市场规模及预测：依服务划分
    • 遗传咨询
    • 检查服务
    • 数据解读
  • 市场规模及预测：依技术划分
    • 次世代定序
    • 聚合酵素链锁反应
    • 微阵列
    • 萤光原位杂合反应
  • 市场规模及预测：依应用领域划分
    • 染色体异常
    • 遗传性疾病
    • 代谢性疾病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊断检查室
    • 研究中心
    • 专科诊所
  • 市场规模及预测：依製程划分
    • 检体采集
    • DNA萃取
    • 定序
    • 数据分析
  • 市场规模及预测：依实施方法划分
    • 侵入性检查
    • 非侵入性
  • 市场规模及预测：依阶段划分
    • 怀孕前
    • 产前检查
    • 出生后

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Natera
  • Invitae
  • Myriad Genetics
  • Progenity
  • Genetic Technologies
  • Perkin Elmer
  • Veritas Genetics
  • Ariosa Diagnostics
  • Billion To One
  • Sema4
  • Color Genomics
  • Genomic Prediction
  • Fulgent Genetics
  • Good Start Genetics
  • Counsyl
  • Gene Dx
  • Cooper Genomics
  • Aperiomics
  • Juno Diagnostics
  • Predictive Laboratories

第九章：关于我们

简介目录
Product Code: GIS10516

Prenatal and Newborn Genetic Testing Market is anticipated to expand from $8.1 billion in 2024 to $16.5 billion by 2034, growing at a CAGR of approximately 7.5%. The Prenatal and Newborn Genetic Testing Market encompasses diagnostic and screening tests conducted during pregnancy and after birth to identify genetic disorders and chromosomal abnormalities. This market is driven by advancements in genomic technologies, rising parental awareness, and increasing demand for early diagnosis. Key segments include non-invasive prenatal testing (NIPT), carrier screening, and newborn screening. As precision medicine evolves, the market is poised for growth, emphasizing personalized healthcare solutions and expanding access to genetic counseling.

The Prenatal and Newborn Genetic Testing Market is experiencing robust expansion, fueled by advancements in genomic technologies and increasing parental awareness. Among the segments, the prenatal screening tests exhibit the highest performance, driven by innovations in non-invasive prenatal testing (NIPT) and the growing preference for early detection of genetic disorders. NIPT, with its high accuracy and safety profile, remains a critical sub-segment, attracting significant attention from healthcare providers and expectant parents alike. Following closely, the newborn genetic testing segment shows promising growth, particularly in metabolic disorder screening and whole-genome sequencing. These sub-segments are gaining momentum due to their potential to identify rare genetic conditions early, facilitating timely interventions. The integration of AI and machine learning in genetic data analysis is enhancing test accuracy and efficiency, further propelling market growth. As personalized medicine continues to evolve, the demand for comprehensive genetic testing solutions is expected to rise, presenting lucrative opportunities for industry stakeholders.

Market Segmentation
TypePrenatal Screening, Newborn Screening, Carrier Testing, Diagnostic Testing
ProductInstruments, Kits and Reagents, Software, Consumables
ServicesGenetic Counseling, Laboratory Services, Data Interpretation
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, Microarray, Fluorescence In Situ Hybridization
ApplicationChromosomal Abnormalities, Genetic Disorders, Metabolic Disorders
End UserHospitals, Diagnostic Laboratories, Research Centers, Specialty Clinics
ProcessSample Collection, DNA Isolation, Sequencing, Data Analysis
ModeInvasive, Non-invasive
StagePreconception, Prenatal, Postnatal

The prenatal and newborn genetic testing market is witnessing a dynamic shift, with a diverse array of new product launches enhancing the competitive landscape. Market share is predominantly held by companies that leverage advanced technologies to offer comprehensive testing solutions. Pricing strategies are increasingly competitive, driven by the need to balance affordability with the high costs of innovation. The introduction of novel testing methodologies is reshaping consumer expectations and expanding the market's reach across various regions. Competition benchmarking reveals a concentrated market with key players investing in research and development to maintain their competitive edge. Regulatory influences are significant, with stringent guidelines shaping product development and market entry strategies. The landscape is further complicated by the varying regulatory environments across regions, necessitating agile compliance strategies. The market is poised for growth, bolstered by technological advancements and increased awareness of genetic testing benefits. This expansive analysis underscores the market's potential, highlighting opportunities for strategic investments and partnerships.

Geographical Overview:

The prenatal and newborn genetic testing market is witnessing notable growth across various regions, each with its unique dynamics. North America leads the market, driven by advanced healthcare infrastructure and increasing awareness about genetic disorders. The presence of key players and extensive research activities further bolster this region's market position. Europe follows closely, with a strong focus on early diagnosis and preventive healthcare. Government initiatives supporting genetic testing and personalized medicine enhance the market's appeal. In Asia Pacific, the market is expanding rapidly due to rising healthcare expenditure and increasing birth rates. Emerging economies like China and India are investing significantly in healthcare technologies, creating lucrative opportunities. Latin America and the Middle East & Africa are emerging as potential growth pockets. In Latin America, improved healthcare access and rising awareness about genetic disorders are key drivers. The Middle East & Africa are recognizing the importance of genetic testing in improving maternal and child health outcomes, fostering market growth.

The Prenatal and Newborn Genetic Testing Market is navigating a complex landscape shaped by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, heightened trade tensions are prompting strategic investments in local biotechnology capabilities to mitigate dependency on foreign imports. China is accelerating its focus on self-sufficiency in genetic testing technologies amid export restrictions, while Taiwan leverages its semiconductor prowess to enhance testing equipment precision. The global market is witnessing robust growth, driven by increasing awareness and technological advancements. By 2035, the market is expected to thrive, contingent on regional collaborations and innovation. Meanwhile, ongoing Middle East conflicts exert pressure on energy prices, indirectly influencing manufacturing costs and supply chain stability across these nations.

Key Trends and Drivers:

The Prenatal and Newborn Genetic Testing Market is on a growth trajectory, propelled by technological advancements and heightened awareness of genetic disorders. Key trends include the increasing adoption of non-invasive prenatal testing (NIPT) due to its accuracy and safety. This trend is complemented by the integration of artificial intelligence and big data analytics, enhancing diagnostic precision and personalized medicine approaches. Additionally, the market is witnessing a surge in demand for comprehensive newborn screening programs, driven by government initiatives and parental awareness. Drivers of this market include the rising prevalence of genetic disorders and congenital anomalies, which necessitate early detection and intervention. The growing emphasis on preventive healthcare and the expansion of healthcare infrastructure in emerging economies further bolster market growth. Moreover, collaborations between healthcare providers and genetic testing companies are fostering innovation and accessibility. Opportunities abound in developing personalized testing kits and expanding telemedicine services, catering to remote and underserved populations. As ethical considerations and regulatory frameworks evolve, the market is poised for sustained expansion, aligning with global health priorities.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Prenatal Screening
    • 4.1.2 Newborn Screening
    • 4.1.3 Carrier Testing
    • 4.1.4 Diagnostic Testing
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Instruments
    • 4.2.2 Kits and Reagents
    • 4.2.3 Software
    • 4.2.4 Consumables
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genetic Counseling
    • 4.3.2 Laboratory Services
    • 4.3.3 Data Interpretation
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Microarray
    • 4.4.4 Fluorescence In Situ Hybridization
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Chromosomal Abnormalities
    • 4.5.2 Genetic Disorders
    • 4.5.3 Metabolic Disorders
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Research Centers
    • 4.6.4 Specialty Clinics
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Sample Collection
    • 4.7.2 DNA Isolation
    • 4.7.3 Sequencing
    • 4.7.4 Data Analysis
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 Invasive
    • 4.8.2 Non-invasive
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preconception
    • 4.9.2 Prenatal
    • 4.9.3 Postnatal

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Mode
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Mode
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Mode
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Mode
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Mode
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Mode
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Mode
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Mode
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Mode
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Mode
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Mode
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Mode
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Mode
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Mode
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Mode
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Mode
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Mode
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Mode
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Mode
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Mode
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Mode
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Mode
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Mode
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Mode
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Natera
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Invitae
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Myriad Genetics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Progenity
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Genetic Technologies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Perkin Elmer
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Veritas Genetics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Ariosa Diagnostics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Billion To One
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Sema4
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Color Genomics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genomic Prediction
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Fulgent Genetics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Good Start Genetics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Counsyl
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Gene Dx
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Cooper Genomics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Aperiomics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Juno Diagnostics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Predictive Laboratories
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us